Literature DB >> 35141025

Trastuzumab aggravates radiation induced cardiotoxicity in mice.

Peiqiang Yi1, Huan Li1, Jun Su1, Jialin Cai2, Cheng Xu1, Jiayi Chen1, Lu Cao1, Min Li1.   

Abstract

Some breast cancer patients with overexpression of human epidermal growth factor receptor 2 need both chest radiotherapy and targeted therapy with trastuzumab (TRZ). The cardiotoxicity associated with combined treatment potentially restricts the clinical benefits of antitumor therapy. There is no consensus on whether and how chest radiotherapy can be given in concurrent with TRZ at present, considering the cardiotoxicity. This study intends to establish an in vitro and in vivo heart injury model by irradiation and TRZ, analyze whether there is a synergistic effect in heart, and to explore the molecular changes. First, an in vitro irradiation model of H9C2 cardiomyocytes was established. The effects of TRZ and radiation on cardiomyocyte injury were observed by cell flow cytometry, CCK-8 test, Western blot, γ-H2AX fluorescence focus formation and cell Reactive Oxygen Species (ROS) content test. Second, the mouse heart injury model was set up by X-ray cardiac irradiation combined with TRZ. Six months later, the cardiac function was analyzed by small animal ultrasound and 18FDG-micro PET/CT. The morphological changes of heart tissue were assessed by histological section. We found that concurrent TRZ aggravates the injury effect of irradiation on cardiomyocytes in vitro. The influence of TRZ might be consequence of inhibiting Akt phosphorylation, promoting the excessive accumulation of ROS in cells and promoting intracellular DNA damage. In animal experiments, the dysfunction of diastolic and myocardial ischemia of mouse heart was observed by echocardiography and 18FDG-micro PET/CT, respectively; myocardial fibrosis and cardiomyocyte apoptosis were also observed. Therefore, our in vitro and in vivo experiments have revealed that TRZ combined irradiation caused more cardiotoxicity than irradiation or TRZ alone. These results suggested that the concurrent management of TRZ and radiotherapy should be carefully made in clinical practice, and more attention is needed on cardiac safety. AJCR
Copyright © 2022.

Entities:  

Keywords:  Trastuzumab; cardiotoxicity; heart; mice; radiation

Year:  2022        PMID: 35141025      PMCID: PMC8822280     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  39 in total

Review 1.  Myocardial substrate metabolism in the normal and failing heart.

Authors:  William C Stanley; Fabio A Recchia; Gary D Lopaschuk
Journal:  Physiol Rev       Date:  2005-07       Impact factor: 37.312

2.  p53 functions in endothelial cells to prevent radiation-induced myocardial injury in mice.

Authors:  Chang-Lung Lee; Everett J Moding; Kyle C Cuneo; Yifan Li; Julie M Sullivan; Lan Mao; Iman Washington; Laura B Jeffords; Rafaela C Rodrigues; Yan Ma; Shiva Das; Christopher D Kontos; Yongbaek Kim; Howard A Rockman; David G Kirsch
Journal:  Sci Signal       Date:  2012-07-24       Impact factor: 8.192

3.  The utility of 18F-fluorodeoxyglucose positron emission tomography for early diagnosis of radiation-induced myocardial damage.

Authors:  Keiichi Jingu; Tomohiro Kaneta; Kenji Nemoto; Azusa Ichinose; Minako Oikawa; Yoshihiro Takai; Yoshihiro Ogawa; Eiko Nakata; Toru Sakayauchi; Kenji Takai; Toshiyuki Sugawara; Kakutaro Narazaki; Hiroshi Fukuda; Shoki Takahashi; Shogo Yamada
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-01       Impact factor: 7.038

4.  Dynamics of γH2AX formation and elimination in mammalian cells after X-irradiation.

Authors:  Denis Firsanov; Anastasia Vasilishina; Andrey Kropotov; Vyacheslav Mikhailov
Journal:  Biochimie       Date:  2012-07-03       Impact factor: 4.079

5.  Low-dose radiation exposure and protection against atherosclerosis in ApoE(-/-) mice: the influence of P53 heterozygosity.

Authors:  R E J Mitchel; M Hasu; M Bugden; H Wyatt; G Hildebrandt; Y-X Chen; N D Priest; S C Whitman
Journal:  Radiat Res       Date:  2013-01-04       Impact factor: 2.841

Review 6.  PI3K pathway alterations in cancer: variations on a theme.

Authors:  T L Yuan; L C Cantley
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

7.  Administration of trastuzumab with heart irradiation induced acute cardiotoxicity in mice.

Authors:  Peiqiang Yi; Huan Li; Yuehua Fang; Jun Su; Cheng Xu; Lu Cao; Min Li; Jiayi Chen
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

8.  HER2 missense mutations have distinct effects on oncogenic signaling and migration.

Authors:  Daniel J Zabransky; Christopher L Yankaskas; Rory L Cochran; Hong Yuen Wong; Sarah Croessmann; David Chu; Shyam M Kavuri; Monica Red Brewer; D Marc Rosen; W Brian Dalton; Ashley Cimino-Mathews; Karen Cravero; Berry Button; Kelly Kyker-Snowman; Justin Cidado; Bracha Erlanger; Heather A Parsons; Kristen M Manto; Ron Bose; Josh Lauring; Carlos L Arteaga; Konstantinos Konstantopoulos; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-27       Impact factor: 11.205

9.  Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy.

Authors:  L Cao; W G Hu; Y M Kirova; Z Z Yang; G Cai; X L Yu; J L Ma; X M Guo; Z M Shao; J Y Chen
Journal:  Cancer Radiother       Date:  2014-03-15       Impact factor: 1.018

Review 10.  Cancer and radiation therapy: current advances and future directions.

Authors:  Rajamanickam Baskar; Kuo Ann Lee; Richard Yeo; Kheng-Wei Yeoh
Journal:  Int J Med Sci       Date:  2012-02-27       Impact factor: 3.738

View more
  1 in total

Review 1.  Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy.

Authors:  Wei Huang; Rong Xu; Bin Zhou; Chao Lin; Yingkun Guo; Huayan Xu; Xia Guo
Journal:  Front Cardiovasc Med       Date:  2022-06-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.